Zynex Inc. (OTCMKTS:ZYXI) shares were down 0.7% during mid-day trading on Tuesday . The company traded as low as $25.91 and last traded at $25.92, approximately 466,033 shares changed hands during trading. A decline of 34% from the average daily volume of 707,648 shares. The stock had previously closed at $26.11.
A number of equities analysts have recently issued reports on ZYXI shares. Northland Securities lowered shares of Zynex from an “outperform” rating to a “market perform” rating and set a $21.00 target price on the stock. in a research report on Tuesday, June 16th. B. Riley lowered shares of Zynex from a “buy” rating to a “neutral” rating in a research report on Monday. They noted that the move was a valuation call. Zacks Investment Research raised Zynex from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a report on Tuesday, March 31st. Finally, HC Wainwright reissued a “neutral” rating and issued a $30.00 target price (up previously from $20.00) on shares of Zynex in a report on Friday, July 10th.
The firm has a market cap of $746.01 million, a price-to-earnings ratio of 102.16 and a beta of 1.05. The firm has a 50 day moving average price of $23.25 and a 200-day moving average price of $15.08.
A number of hedge funds have recently made changes to their positions in ZYXI. State Street Corp raised its stake in Zynex by 8.4% in the 4th quarter. State Street Corp now owns 323,063 shares of the company’s stock valued at $2,543,000 after purchasing an additional 25,087 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Zynex by 24.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 40,453 shares of the company’s stock valued at $319,000 after purchasing an additional 8,042 shares during the last quarter. Barclays PLC raised its stake in Zynex by 105.6% in the 4th quarter. Barclays PLC now owns 15,810 shares of the company’s stock valued at $124,000 after purchasing an additional 8,122 shares during the last quarter. Citigroup Inc. raised its stake in Zynex by 310.6% in the 4th quarter. Citigroup Inc. now owns 3,170 shares of the company’s stock valued at $25,000 after purchasing an additional 2,398 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in Zynex in the 4th quarter valued at about $345,000. 0.05% of the stock is owned by hedge funds and other institutional investors.
Zynex Company Profile (OTCMKTS:ZYXI)
Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.
Recommended Story: Momentum Indicator: Relative Strength Index
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.